Improvement in both Raynaud disease and hyperhidrosis in response to botulinum toxin type a treatment

Journal of Cutaneous Medicine and Surgery

Volumn 12, Issue 4, 2008, Pages 189-193

  Kossintseva, Irèn ^a   Barankin, Benjamin ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b The Dermatology Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ALLEGRA D; BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE; FEXOFENADINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; NEUROPEPTIDE; NORADRENALIN; PENICILLIN G; SNARE PROTEIN; SUBSTANCE P; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ADULT; ANTICHOLINERGIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; CASE REPORT; DRUG EFFICACY; FEMALE; FOLLOW UP; HAND DISEASE; HAND PALM; HAY FEVER; HUMAN; HYPERHIDROSIS; PAIN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAYNAUD PHENOMENON; SKIN COLOR; SKIN SWELLING; TREATMENT OUTCOME;

ADULT; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; HYPERHIDROSIS; NEUROMUSCULAR AGENTS; RAYNAUD DISEASE;

EID: 51349099822     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2008.07044     Document Type: Article

References (23)

1. Gerber SH, Sudhof TC. Molecular determinants of regulated exocytosis. Diabetes 2002;51 Suppl 1:S3-11.
2. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365: 160-3.
3. Verderio C, Rossetto O, Grumelli C, et al. Entering neurons: botulinum toxins and synaptic vesicle recycling. EMBO Rep 2006; 7:995-9.
4. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981;33:155-88.
5. Hallett M. One man's poison - clinical applications of botulinum toxin. N Engl J Med 1999;341:118-20.
6. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-93.
7. Odderson IR. Hyperhidrosis treated by botulinum A exotoxin. Dermatol Surg 1998;24:1237-41.
8. Heckmann M, Ceballos-Baumann AO, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001;344:488-93.
9. Haferkamp A, Krengel U, Reitz A, et al. Are botulinum-A toxin injections into the detrusor of patients with neurogenic detrusor overactivity safe? Ultrastructural data of detrusor biopsies. Neurourol Urodyn 2003;22:499-500.
10. de Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 1999;96: 3200-5.
11. Morris JL, Jobling P, Gibbins IL. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilatior neurons. Am J Physiol Heart Circ Physiol 2001; 281:H2124-32.
12. Morris JL, Jobling P, Gibbins IL. Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons. Am J Physiol Heart Circ Physiol 2002;283: H2627-35.
13. Ansiaux R, Baudelet C, Cron GO, et al. Botulinum toxin potentiates cancer radiotherapy and chemotherapy. Clin Cancer Res 2006;12:1276-83.
14. Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg 2007;119:217-26.
15. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125-33.
16. Türk N, Ilhan S, Alp R, Sur H. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol 2005;28:161-2. 17 Aurora S. Botulinum toxin type A for the treatment of migraine. Expert Opin Pharmacother 2006;7:1085-95.
17. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245-58.
18. Rapp DE, Turk KW, Bales GT, Coock SP. Botulinum toxin type A inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 2006;175:1138-42.
19. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004;44:35-43.
20. Carlton SM, Hargett GL, Coggeshall RE. Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skin. Neurosci Lett 1995;197:25-8.
21. Wheeler-Aceto H, Porreca F, Cowan A. The rat paw formalin test: comparison of noxious agents. Pain 1990;40:229-38.
22. Stadlmaier E, Müller T, Hermann J, Graninger W. Raynaud's phenomenon: treatment with botulinum toxin [abstract]. Ann Rheum Dis 2005;64(Suppl III):275.
23. Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study. Eur J Clin Invest 2004;34:312-3.